Literature DB >> 24918595

Lessons learned from scale-up of voluntary medical male circumcision focusing on adolescents: benefits, challenges, and potential opportunities for linkages with adolescent HIV, sexual, and reproductive health services.

Emmanuel Njeuhmeli1, Karin Hatzold, Elizabeth Gold, Hally Mahler, Katharine Kripke, Kim Seifert-Ahanda, Delivette Castor, Webster Mavhu, Owen Mugurungi, Gertrude Ncube, Sifuni Koshuma, Sema Sgaier, Shanti R Conly, Susan Kasedde.   

Abstract

BACKGROUND AND METHODS: By December 2013, it was estimated that close to 6 million men had been circumcised in the 14 priority countries for scaling up voluntary medical male circumcision (VMMC), the majority being adolescents (10-19 years). This article discusses why efforts to scale up VMMC should prioritize adolescent men, drawing from new evidence and experiences at the international, country, and service delivery levels. Furthermore, we review the extent to which VMMC programs have reached adolescents, addressed their specific needs, and can be linked to their sexual and reproductive health and other key services. RESULTS AND DISCUSSION: In priority countries, adolescents represent 34%-55% of the target population to be circumcised, whereas program data from these countries show that adolescents represent between 35% and 74% of the circumcised men. VMMC for adolescents has several advantages: uptake of services among adolescents is culturally and socially more acceptable than for adults; there are fewer barriers regarding sexual abstinence during healing or female partner pressures; VMMC performed before the age of sexual debut has maximum long-term impact on reducing HIV risk at the individual level and consequently reduces the risk of transmission in the population. Offered as a comprehensive package, adolescent VMMC can potentially increase public health benefits and offers opportunities for addressing gender norms. Additional research is needed to assess whether current VMMC services address the specific needs of adolescent clients, to test adapted tools, and to assess linkages between VMMC and other adolescent-focused HIV, health, and social services.

Entities:  

Mesh:

Year:  2014        PMID: 24918595     DOI: 10.1097/QAI.0000000000000179

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  33 in total

1.  Risk Compensation Following Medical Male Circumcision: Results from a 1-Year Prospective Cohort Study of Young School-Going Men in KwaZulu-Natal, South Africa.

Authors:  K Govender; G George; S Beckett; C Montague; J Frohlich
Journal:  Int J Behav Med       Date:  2018-02

Review 2.  Messaging matters: achieving equity in the HIV response through public health communication.

Authors:  Tamara Taggart; Tiarney D Ritchwood; Kate Nyhan; Yusuf Ransome
Journal:  Lancet HIV       Date:  2021-06       Impact factor: 16.070

3.  Effectiveness of Voluntary Medical Male Circumcision for Human Immunodeficiency Virus Prevention in Rakai, Uganda.

Authors:  Gideon Loevinsohn; Godfrey Kigozi; Joseph Kagaayi; Maria J Wawer; Fred Nalugoda; Larry W Chang; Thomas C Quinn; David Serwadda; Steven J Reynolds; Lisa Nelson; Lisa Mills; Stella Alamo; Gertrude Nakigozi; Geoffrey Kabuye; Robert Ssekubugu; Aaron A R Tobian; Ronald H Gray; M Kathryn Grabowski
Journal:  Clin Infect Dis       Date:  2021-10-05       Impact factor: 20.999

4.  Age Targeting of Voluntary Medical Male Circumcision Programs Using the Decision Makers' Program Planning Toolkit (DMPPT) 2.0.

Authors:  Katharine Kripke; Marjorie Opuni; Melissa Schnure; Sema Sgaier; Delivette Castor; Jason Reed; Emmanuel Njeuhmeli; John Stover
Journal:  PLoS One       Date:  2016-07-13       Impact factor: 3.240

5.  Modeling Impact and Cost-Effectiveness of Increased Efforts to Attract Voluntary Medical Male Circumcision Clients Ages 20-29 in Zimbabwe.

Authors:  Katharine Kripke; Karin Hatzold; Owen Mugurungi; Gertrude Ncube; Sinokuthemba Xaba; Elizabeth Gold; Kim Seifert Ahanda; Natalie Kruse-Levy; Emmanuel Njeuhmeli
Journal:  PLoS One       Date:  2016-10-26       Impact factor: 3.240

6.  Early Resumption of Sex following Voluntary Medical Male Circumcision amongst School-Going Males.

Authors:  Gavin George; Kaymarlin Govender; Sean Beckett; Carl Montague; Janet Frohlich
Journal:  PLoS One       Date:  2016-12-08       Impact factor: 3.240

7.  Effectiveness of and Financial Returns to Voluntary Medical Male Circumcision for HIV Prevention in South Africa: An Incremental Cost-Effectiveness Analysis.

Authors:  Markus Haacker; Nicole Fraser-Hurt; Marelize Gorgens
Journal:  PLoS Med       Date:  2016-05-03       Impact factor: 11.069

Review 8.  Adolescent Sexual and Reproductive Health Services and Implications for the Provision of Voluntary Medical Male Circumcision: Results of a Systematic Literature Review.

Authors:  Michelle R Kaufman; Marina Smelyanskaya; Lynn M Van Lith; Elizabeth C Mallalieu; Aliza Waxman; Karin Hatzhold; Arik V Marcell; Susan Kasedde; Gissenge Lija; Nina Hasen; Gertrude Ncube; Julia L Samuelson; Collen Bonnecwe; Kim Seifert-Ahanda; Emmanuel Njeuhmeli; Aaron A R Tobian
Journal:  PLoS One       Date:  2016-03-03       Impact factor: 3.240

9.  Safety and Efficacy of the PrePex Male Circumcision Device: Results From Pilot Implementation Studies in Mozambique, South Africa, and Zambia.

Authors:  Paul Feldblum; Neil Martinson; Bruce Bvulani; Noah Taruberekera; Mehebub Mahomed; Namwinga Chintu; Minja Milovanovic; Catherine Hart; Scott Billy; Edgar Necochea; Alick Samona; Miriam Mhazo; Debora Bossemeyer; Jaim Jou Lai; Limakatso Lebinai; Tigistu A Ashengo; Lucinda Macaringue; Valentine Veena; Karin Hatzold
Journal:  J Acquir Immune Defic Syndr       Date:  2016-06-01       Impact factor: 3.731

10.  Safety Profile of PrePex Male Circumcision Device and Client Satisfaction With Adolescent Males Aged 13-17 Years in Zimbabwe.

Authors:  Mafuta Tshimanga; Karin Hatzold; Owen Mugurungi; Tonderayi Mangwiro; Getrude Ncube; Sinokuthemba Xaba; Pesanai Chatikobo; Patricia Gundidza; Christopher Samkange; Roy Dhlamini; Munyaradzi Murwira; Gerald Gwinji
Journal:  J Acquir Immune Defic Syndr       Date:  2016-06-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.